Roche Gets Second European Approval for Alzheimer's Test
The test uses common cutoffs to help clinicians identify amyloid pathology and could reduce reliance on PET scans and spinal fluid testing.
7 Articles
7 Articles
Roche gets European approval for Alzheimer’s diagnosis blood test
Swiss pharmaceutical company Roche has received European approval for a blood test that can detect and rule out Alzheimer’s disease, offering a simpler and less invasive alternative to current diagnostic methods.
Roche Receives CE Mark for Alzheimer’s Disease Blood Test
The new assay measures pTau217 protein to help clinicians identify amyloid pathology in patients experiencing cognitive decline. Roche received the CE mark for its Elecsys pTau217 blood test, an assay designed to detect Alzheimer’s disease pathology. Developed in collaboration with Eli Lilly and Company, the test measures phosphorylated tau (pTau) 217 protein, which serves as an indicator of amyloid pathology. The test is intended to rule in or …
Roche, a pharmaceutical company, has received the green light from the EU for a new blood test to enable early detection of Alzheimer's disease, thus avoiding costly and painful diagnostic procedures for patients.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
